Mosaic Biosciences

Mosaic Biosciences: Biologics Brief

Science EN ↓ 6 episodios

The science and strategy of making protein therapeutic medicines. The Biologics Brief is a podcast about the science and strategy behind making protein therapeutic medicines. Hosted by the scientists at Mosaic Biosciences, a biologics discovery CRO, each episode unpacks the real decisions behind antibody discovery and biologics development, the same conversations we have with our partners every day. From choosing the right discovery platform to evaluating a CRO, scoping a campaign, and navigating difficult targets, we get practical about what actually moves a program forward. Whether you're bu...

No dejes de visitar la web del podcast y apoyar a su creador: www.buzzsprout.com

Autor

Mosaic Biosciences

Categoría

Science

Web del podcast

www.buzzsprout.com

Último episodio

12 de oct. de 2026

¿Dónde escuchar?

Podcasts en la app Replaio Radio Muy pronto

Los podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts

Descárgala en Google Play Instálala gratis Android 10 M+ de descargas · valoración de 4,7+ iOS muy pronto

Episodios

Episode 6: Outsourcing Antibody Discovery in Europe: What Biotechs Should Ask Before Choosing a CRO 12.10.2026

Send us Fan Mail Mosaic’s Tracey Mullen and Thijs, Senior Director of Business Development for Europe, on choosing a CRO in Europe: funding, scope, and the questions to ask first. 🎧 Listen now and subscribe wherever you get your podcasts. mosaicbio.com

What's the Best Antibody Discovery Platform? It Depends on the Biology 29.09.2026

Send us Fan Mail In this episode of the Biologics Brief, Mosaic Biosciences' Chief Strategy Officer Tracey Mullen sits down with Lippy Lippincott, Chief Strategy Officer at AbTherix, for a wide-ranging conversation on how experienced antibody discovery scientists actually choose a discovery strategy, and why the best ones rarely start with the platform. Together, Tracey and Lippy challenge th...

From Discovery to Drug: What Antibody Developability Really Means 25.08.2026

Send us Fan Mail In this episode of the Biologics Brief, Mosaic Biosciences' Chief Strategy Officer Tracey Mullen sits down with Stacy Capehart, Director of Data Sciences at Mosaic, to talk about what happens after you find a promising antibody, and why finding one is not the same as finding a therapeutic candidate. The conversation covers what developability actually means, the most common w...

In Vivo Antibody Discovery with Humanized Transgenic Mice 17.08.2026

Send us Fan Mail In this episode of the Biologics Brief, Mosaic Biosciences' Chief Strategy Officer Tracey Mullen leads a conversation on in vivo antibody discovery using humanized transgenic mice. She's joined by Dan Rohrer (Chief Technology Officer, AbTherx), along with Mosaic's Eric Firfine (Chief Scientific Officer), Maria Lo (Head of In Vivo Antibody Discovery), and Stacy Capeh...

Single B Cell Discovery: Platforms, Trade-offs, and How to Actually Choose 05.08.2026

Send us Fan Mail Single B cell discovery has become one of the most powerful tools in antibody drug discovery, but with so many platforms on the market, how do you know which one is right for your campaign? In this special Spotlight episode of The Biologics Brief, Mosaic Biosciences CSO Tracey Mullen sits down with Director of Antibody Discovery Christina Palmer to break down everything you need t...

How to Choose a CRO for Antibody Discovery 28.05.2026

Your antibody program doesn’t fail because you picked the “wrong platform” as often as it fails because you picked the wrong partner. We get specific about how to choose a preclinical CRO for antibody discovery by starting with the one thing that should drive every decision: the target clinical profile. If the CRO can’t translate your clinical goals into a practical, testable preclinical plan, you...

Escucha el podcast Mosaic Biosciences: Biologics Brief en Replaio

Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno

Descárgala en Google Play

Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos